Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer.

Nature reviews. Urology·2026
Same author

Heterologous vaccination with a next-generation vaccinia virus and Ad26 induces Ebola-specific immunity in macaques.

NPJ vaccines·2026
Same author

Diagnostic and prognostic utility of PSMA-PET/CT in node-metastatic prostate cancer.

BJU international·2026
Same author

Total Gleason Pattern 4 Length Outperforms Grade Group and Clinical Models in Predicting Oncologic Outcomes in Grade Group 2-4 Prostate Cancer.

medRxiv : the preprint server for health sciences·2026
Same author

Reply to: Methodologic Considerations for Subsequent Colorectal Cancer in Survivors of Childhood Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Comparison of Cancer Detection Between Transrectal and Transperineal Prostate Biopsy in an Active Surveillance Cohort.

European urology focus·2026

Related Experiment Video

Updated: May 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized ControlledTrial.

Lee W Jones1,2, Chaya S Moskowitz1, Catherine P Lee1

  • 1Memorial Sloan Kettering Cancer Center, New York, New York.

JAMA Oncology
|July 18, 2024
PubMed
Summary
This summary is machine-generated.

Exercise therapy is feasible and safe for localized prostate cancer patients, with 225 minutes per week recommended for Phase 2 trials. This approach shows promising tumor biological activity.

More Related Videos

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.4K
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.1K

Related Experiment Videos

Last Updated: May 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.4K
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.1K

Area of Science:

  • Oncology
  • Exercise Physiology
  • Clinical Trials

Background:

  • Postdiagnosis exercise is linked to reduced prostate cancer mortality.
  • The feasibility and tumor biological effects of exercise therapy remain unknown.

Purpose of the Study:

  • To determine the recommended Phase 2 dose of exercise therapy for prostate cancer patients.
  • To assess the feasibility and tumor biological activity of exercise interventions.

Main Methods:

  • A single-center, Phase 1a dose-finding trial involving 53 men with localized prostate cancer.
  • Six escalated doses of moderate-intensity treadmill walking (90-450 min/week) delivered remotely.
  • Feasibility assessed by relative exercise dose intensity (REDI); tumor proliferation (Ki67) and PSA levels as activity endpoints.

Main Results:

  • All tested exercise doses were feasible, with patients achieving ≥75% REDI.
  • No serious adverse events were recorded.
  • 225 minutes per week was identified as the recommended Phase 2 dose, showing a trend towards reduced tumor proliferation and PSA levels.

Conclusions:

  • Neoadjuvant exercise therapy is a feasible and safe intervention for localized prostate cancer.
  • Exercise therapy demonstrates promising tumor biological activity, warranting further investigation in Phase 2 trials.